

Amendments to the Claims:

Please amend the claims as follows.

Listing of Claims:

Please cancel claims 16, 46, and 47. The following list of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A vaccine for protecting a horse against diseases associated with EHV-1, EHV-4 or a combination thereof comprising:

chemically inactivated EHV-1 KyA virus; and
an adjuvant which includes cross-linked olefinically unsaturated carboxylic acid polymer.

2. (Previously Presented) The vaccine of claim 1 wherein the EHV-1 KyA virus is chemically inactivated by treatment with a chemical inactivating agent which includes a compound selected from the group consisting of ethylenimine, binary ethylenimine, acétylethylenimine and mixtures thereof.

3. (Original) The vaccine of claim 2 wherein the EHV-1 KyA virus is chemically inactivated by treatment with binary ethylenimine.

4. (Original) The vaccine of claim 1 further comprising inactivated EHV-4.

5. (Original) The vaccine of claim 1 further comprising inactivated equine influenza virus.

6. (Original) The vaccine of claim 5 wherein the inactivated equine influenza virus includes inactivated EIV virus subtype A1.

7. (Canceled)

8. (Original) The vaccine of claim 5 wherein the inactivated equine influenza virus includes inactivated EIV virus subtype A2.

9. (Canceled)

10. (Original) The vaccine of claim 5 comprising inactivated EIV virus subtype A1 and inactivated EIV virus subtype A2.
11. (Canceled)
12. (Original) The vaccine of claim 1 wherein said vaccine is capable of protecting horses against EHV-1 and EHV-4.
13. (Original) The vaccine of claim 1 wherein the cross-linked olefinically unsaturated carboxylic acid polymer includes cross-linked acrylic acid polymer.
14. (Previously Presented) A vaccine for protecting a horse against diseases associated with EHV-1, EHV-4 or a combination thereof comprising:

EHV-1 KyA virus inactivated by treatment with a chemical inactivating agent which includes ethylenimine, binary ethylenimine, acetylenimine or a mixture thereof; and

a bioadhesive adjuvant which includes a cross-linked olefinically unsaturated carboxylic acid polymer.
15. (Original) The vaccine of claim 14 wherein the chemical inactivating agent includes binary ethylenimine.
16. (Canceled)
17. (Original) A method for protecting a horse against diseases associated with EHV-1, EHV-4 or a combination thereof comprising:

administering to said horse a vaccine comprising chemically inactivated EHV-1 KyA virus and an adjuvant which includes cross-linked olefinically unsaturated carboxylic acid polymer.

18. (Original) The method of claim 17 wherein administering the vaccine to said horse comprises:

parenterally administering the vaccine; and
intranasally administering the vaccine.

19. (Original) The method of claim 18 wherein administering the vaccine to said horse comprises:

parenterally administering the vaccine at least once in a first step; and
intranasally administering the vaccine in a subsequent step.

20. (Original) The method of claim 17 wherein the vaccine further comprises inactivated EHV-4.

21. (Original) The method of claim 17 wherein the vaccine further comprises inactivated equine influenza virus.

22. (Original) The method of claim 21 wherein the vaccine comprises inactivated EIV virus subtype A1 and inactivated EIV virus subtype A2.

23.-26. (Canceled)

27. (Original) A kit comprising in combination, (1) a dispenser capable of administering a vaccine to a horse; and (2) a composition to protect against diseases associated with EHV-1, EHV-4 or a combination thereof, wherein the composition comprises:

chemically inactivated EHV-1 KyA virus; and
an adjuvant which includes cross-linked olefinically unsaturated carboxylic acid polymer.

28. (Original) The kit of claim 27 wherein the dispenser is capable of dispensing its contents as droplets; and the composition is capable of protecting against diseases associated with EHV-1, EHV-4 or a combination thereof when administered intranasally.

29.-31. (Canceled)

32. (Previously Presented) A vaccine for protecting a horse against diseases associated with EHV-1, EHV-4 or a combination thereof comprising:

EHV-1 KyA virus inactivated by treatment with a chemical inactivating agent which includes ethylenimine, binary ethylenimine, acetythylenimine or a mixture thereof; and

a bioadhesive adjuvant which includes a cross-linked acrylic acid polymer.

33. (Previously Presented) The vaccine of claim 32 further comprising inactivated EHV-4.

34. (Previously Presented) The vaccine of claim 32 further comprising inactivated equine influenza virus.

35. (Previously Presented) The vaccine of claim 34 wherein the inactivated equine influenza virus includes inactivated EIV virus subtype A1.

36. (Canceled)

37. (Previously Presented) The vaccine of claim 34 wherein the inactivated equine influenza virus includes inactivated EIV virus subtype A2.

38. (Canceled)

39. (Previously Presented) The vaccine of claim 34 comprising inactivated EIV virus subtype A1 and inactivated EIV virus subtype A2.

40. (Canceled)

41. (Previously Presented) The vaccine of claim 32 further comprising gentamicin.

42. (Previously Presented) The vaccine of claim 32 comprising EHV-1 KyA virus inactivated by treatment with a chemical inactivating agent which includes binary ethylenimine.

43. (Previously Presented) The vaccine of claim 32 wherein the cross-linked acrylic acid polymer has a viscosity of no more than about 20,000 cPs at 20 rpm as a 1.0 wt.% aqueous solution at pH 7.5.

44. (Previously Presented) The vaccine of claim 14 further comprising inactivated EHV-4.

45. (Previously Presented) The vaccine of claim 14 further comprising inactivated EIV virus subtype A1 and inactivated EIV virus subtype A2.

46.-47. (Canceled)

48. (Previously Presented) The kit of claim 27 wherein the chemically inactivated EHV-1 KyA virus is chemically inactivated by treatment with binary ethylenimine.

49. (Previously Presented) The kit of claim 27 wherein the composition further comprises inactivated EIV virus subtype A1 and inactivated EIV virus subtype A2.